(1->4)-beta-D-glucan multiple interactions ISO RGD:1317597 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of GABARAPL1 mRNA CTD PMID:36331819 1,1-dichloroethene decreases expression ISO RGD:1317597 6480464 vinylidene chloride results in decreased expression of GABARAPL1 mRNA CTD PMID:26682919 1,2-dimethylhydrazine multiple interactions ISO RGD:1317597 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in increased expression of GABARAPL1 mRNA CTD PMID:22206623 1,2-dimethylhydrazine affects expression ISO RGD:1317597 6480464 1, 2-Dimethylhydrazine affects the expression of GABARAPL1 mRNA CTD PMID:22206623 17beta-estradiol decreases expression EXP 6480464 Estradiol results in decreased expression of GABARAPL1 mRNA CTD PMID:32145629 17beta-estradiol decreases expression ISO RGD:1317596 6480464 Estradiol results in decreased expression of GABARAPL1 mRNA CTD PMID:31614463 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1317597 6480464 [decitabine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of GABARAPL1 mRNA CTD PMID:15251184 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of GABARAPL1 mRNA CTD PMID:34747641 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of GABARAPL1 mRNA CTD PMID:32109520 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO RGD:1317597 6480464 Tetrachlorodibenzodioxin affects the expression of GABARAPL1 mRNA CTD PMID:21570461 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1317596 6480464 Tetrachlorodibenzodioxin results in increased expression of GABARAPL1 mRNA CTD PMID:20106945 , PMID:21632981 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of GABARAPL1 mRNA CTD PMID:21215274 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO RGD:1317597 6480464 Tetrachlorodibenzodioxin results in decreased expression of GABARAPL1 mRNA CTD PMID:15251184 , PMID:19770486 3,4-methylenedioxymethamphetamine increases expression ISO RGD:1317597 6480464 N-Methyl-3, 4-methylenedioxyamphetamine results in increased expression of GABARAPL1 mRNA CTD PMID:20188158 4,4'-sulfonyldiphenol multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of GABARAPL1 mRNA CTD PMID:36041667 4-hydroxynon-2-enal increases expression ISO RGD:1317597 6480464 4-hydroxy-2-nonenal results in increased expression of GABARAPL1 mRNA CTD PMID:19191707 5-aza-2'-deoxycytidine decreases expression ISO RGD:1317597 6480464 Decitabine results in decreased expression of GABARAPL1 mRNA CTD PMID:15251184 5-aza-2'-deoxycytidine increases expression ISO RGD:1317596 6480464 Decitabine results in increased expression of GABARAPL1 mRNA CTD PMID:19194470 5-aza-2'-deoxycytidine multiple interactions ISO RGD:1317597 6480464 [Decitabine co-treated with Tetrachlorodibenzodioxin] results in decreased expression of GABARAPL1 mRNA CTD PMID:15251184 5-aza-2'-deoxycytidine affects expression ISO RGD:1317596 6480464 Decitabine affects the expression of GABARAPL1 mRNA CTD PMID:17145863 6-propyl-2-thiouracil decreases expression EXP 6480464 Propylthiouracil results in decreased expression of GABARAPL1 mRNA CTD PMID:30047161 acetamide decreases expression EXP 6480464 acetamide results in decreased expression of GABARAPL1 mRNA CTD PMID:31881176 acrylamide decreases expression EXP 6480464 Acrylamide results in decreased expression of GABARAPL1 mRNA CTD PMID:28959563 adefovir pivoxil decreases expression ISO RGD:1317596 6480464 adefovir dipivoxil results in decreased expression of GABARAPL1 mRNA CTD PMID:25596134 aflatoxin B1 increases expression ISO RGD:1317596 6480464 Aflatoxin B1 results in increased expression of GABARAPL1 mRNA CTD PMID:21641981 all-trans-retinoic acid increases expression ISO RGD:1317596 6480464 Tretinoin results in increased expression of GABARAPL1 mRNA CTD PMID:23724009 more ... amitrole decreases expression EXP 6480464 Amitrole results in decreased expression of GABARAPL1 mRNA CTD PMID:30047161 atrazine increases expression ISO RGD:1317596 6480464 Atrazine results in increased expression of GABARAPL1 mRNA CTD PMID:22378314 avobenzone increases expression ISO RGD:1317596 6480464 avobenzone results in increased expression of GABARAPL1 mRNA CTD PMID:31016361 benzene decreases expression ISO RGD:1317597 6480464 Benzene results in decreased expression of GABARAPL1 mRNA CTD PMID:15120971 benzo[a]pyrene increases expression ISO RGD:1317597 6480464 Benzo(a)pyrene results in increased expression of GABARAPL1 mRNA CTD PMID:21569818 benzo[a]pyrene increases expression ISO RGD:1317596 6480464 Benzo(a)pyrene results in increased expression of GABARAPL1 mRNA CTD PMID:20106945 more ... benzoates increases expression ISO RGD:1317596 6480464 Benzoates analog results in increased expression of GABARAPL1 mRNA CTD PMID:29472718 beta-naphthoflavone increases expression ISO RGD:1317596 6480464 beta-Naphthoflavone results in increased expression of GABARAPL1 mRNA CTD PMID:19737606 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of GABARAPL1 mRNA CTD PMID:25181051 bisphenol A multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of GABARAPL1 mRNA CTD PMID:36041667 bisphenol A increases expression ISO RGD:1317597 6480464 bisphenol A results in increased expression of GABARAPL1 mRNA CTD PMID:32156529 bisphenol A decreases expression ISO RGD:1317597 6480464 bisphenol A results in decreased expression of GABARAPL1 mRNA CTD PMID:33221593 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of GABARAPL1 mRNA CTD PMID:32145629 bisphenol A affects expression ISO RGD:1317596 6480464 bisphenol A affects the expression of GABARAPL1 mRNA CTD PMID:30903817 bisphenol F multiple interactions EXP 6480464 [bisphenol A co-treated with bisphenol F co-treated with bis(4-hydroxyphenyl)sulfone] results in decreased expression of GABARAPL1 mRNA CTD PMID:36041667 bortezomib increases expression ISO RGD:1317596 6480464 Bortezomib results in increased expression of GABARAPL1 mRNA CTD PMID:20977926 cadmium dichloride decreases expression ISO RGD:1317596 6480464 Cadmium Chloride results in decreased expression of GABARAPL1 mRNA CTD PMID:25596134 carbon nanotube decreases expression ISO RGD:1317597 6480464 Nanotubes more ... CTD PMID:25554681 , PMID:25620056 chloroacetaldehyde decreases expression ISO RGD:1317596 6480464 chloroacetaldehyde results in decreased expression of GABARAPL1 mRNA CTD PMID:25596134 cidofovir anhydrous decreases expression ISO RGD:1317596 6480464 Cidofovir results in decreased expression of GABARAPL1 mRNA CTD PMID:25596134 cisplatin increases expression ISO RGD:1317597 6480464 Cisplatin results in increased expression of GABARAPL1 mRNA CTD PMID:21074548 cisplatin increases expression ISO RGD:1317596 6480464 Cisplatin results in increased expression of GABARAPL1 mRNA CTD PMID:25596134 , PMID:27594783 clodronic acid increases expression ISO RGD:1317596 6480464 Clodronic Acid results in increased expression of GABARAPL1 mRNA CTD PMID:25596134 cobalt dichloride increases expression ISO RGD:1317596 6480464 cobaltous chloride results in increased expression of GABARAPL1 mRNA CTD PMID:19320972 , PMID:19376846 cobalt dichloride increases expression EXP 6480464 cobaltous chloride results in increased expression of GABARAPL1 mRNA CTD PMID:24386269 copper atom multiple interactions ISO RGD:1317596 6480464 [NSC 689534 binds to Copper] which results in increased expression of GABARAPL1 mRNA CTD PMID:20971185 copper atom multiple interactions ISO RGD:1317597 6480464 [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GABARAPL1 mRNA CTD PMID:15467011 copper(0) multiple interactions ISO RGD:1317596 6480464 [NSC 689534 binds to Copper] which results in increased expression of GABARAPL1 mRNA CTD PMID:20971185 copper(0) multiple interactions ISO RGD:1317597 6480464 [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of GABARAPL1 mRNA CTD PMID:15467011 copper(II) sulfate increases expression ISO RGD:1317596 6480464 Copper Sulfate results in increased expression of GABARAPL1 mRNA CTD PMID:19549813 crotonaldehyde increases expression ISO RGD:1317596 6480464 2-butenal results in increased expression of GABARAPL1 mRNA CTD PMID:20471460 CU-O LINKAGE increases expression ISO RGD:1317596 6480464 cupric oxide results in increased expression of GABARAPL1 mRNA CTD PMID:22077320 cyclosporin A increases expression ISO RGD:1317596 6480464 Cyclosporine results in increased expression of GABARAPL1 mRNA CTD PMID:20106945 more ... cytarabine decreases expression ISO RGD:1317596 6480464 Cytarabine results in decreased expression of GABARAPL1 mRNA CTD PMID:21198554 diallyl trisulfide decreases expression ISO RGD:1317596 6480464 diallyl trisulfide results in decreased expression of GABARAPL1 mRNA CTD PMID:34995734 dibenzofurans increases expression ISO RGD:1317597 6480464 Dibenzofurans results in increased expression of GABARAPL1 mRNA CTD PMID:34254344 dibutyl phthalate increases expression ISO RGD:1317597 6480464 Dibutyl Phthalate results in increased expression of GABARAPL1 mRNA CTD PMID:21266533 dibutyl phthalate increases expression EXP 6480464 Dibutyl Phthalate results in increased expression of GABARAPL1 mRNA CTD PMID:21266533 dicrotophos decreases expression ISO RGD:1317596 6480464 dicrotophos results in decreased expression of GABARAPL1 mRNA CTD PMID:28302478 dioxygen decreases expression ISO RGD:1317596 6480464 Oxygen deficiency results in decreased expression of GABARAPL1 mRNA CTD PMID:25596134 doxorubicin increases expression ISO RGD:1317596 6480464 Doxorubicin results in increased expression of GABARAPL1 mRNA CTD PMID:29803840 enniatin decreases expression EXP 6480464 enniatins results in decreased expression of GABARAPL1 mRNA CTD PMID:27163883 ethanol increases expression ISO RGD:1317597 6480464 Ethanol results in increased expression of GABARAPL1 mRNA CTD PMID:30319688 ethanol affects splicing ISO RGD:1317597 6480464 Ethanol affects the splicing of GABARAPL1 mRNA CTD PMID:30319688 folic acid multiple interactions ISO RGD:1317597 6480464 [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in increased expression of GABARAPL1 mRNA CTD PMID:22206623 glafenine decreases expression EXP 6480464 Glafenine results in decreased expression of GABARAPL1 mRNA CTD PMID:24136188 hydrogen peroxide affects expression ISO RGD:1317596 6480464 Hydrogen Peroxide affects the expression of GABARAPL1 mRNA CTD PMID:20044591 hydrogen peroxide decreases secretion ISO RGD:1317597 6480464 Hydrogen Peroxide results in decreased secretion of GABARAPL1 mRNA CTD PMID:21179422 hydrogen peroxide multiple interactions ISO RGD:1317596 6480464 [Hydrogen Peroxide co-treated with Theophylline] results in increased expression of GABARAPL1 protein CTD PMID:18951874 inulin multiple interactions ISO RGD:1317597 6480464 [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of GABARAPL1 mRNA CTD PMID:36331819 isoprenaline increases expression ISO RGD:1317597 6480464 Isoproterenol results in increased expression of GABARAPL1 mRNA CTD PMID:20003209 leflunomide increases expression EXP 6480464 leflunomide results in increased expression of GABARAPL1 mRNA CTD PMID:24136188 mercury dibromide increases expression ISO RGD:1317596 6480464 mercuric bromide results in increased expression of GABARAPL1 mRNA CTD PMID:26272509 methimazole decreases expression EXP 6480464 Methimazole results in decreased expression of GABARAPL1 mRNA CTD PMID:30047161 methylisothiazolinone increases expression ISO RGD:1317596 6480464 2-methyl-4-isothiazolin-3-one results in increased expression of GABARAPL1 mRNA CTD PMID:31629900 methylmercury chloride increases expression ISO RGD:1317596 6480464 methylmercuric chloride results in increased expression of GABARAPL1 mRNA CTD PMID:28001369 methylseleninic acid increases expression ISO RGD:1317596 6480464 methylselenic acid results in increased expression of GABARAPL1 mRNA CTD PMID:18548127 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal increases expression ISO RGD:1317596 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of GABARAPL1 mRNA CTD PMID:31806706 N-methylformamide increases expression ISO RGD:1317597 6480464 methylformamide analog results in increased expression of GABARAPL1 mRNA, methylformamide results in increased expression of GABARAPL1 mRNA CTD PMID:17040096 nickel atom increases expression ISO RGD:1317596 6480464 Nickel results in increased expression of GABARAPL1 mRNA CTD PMID:23195993 nickel sulfate increases expression ISO RGD:1317596 6480464 nickel sulfate results in increased expression of GABARAPL1 mRNA CTD PMID:22714537 niclosamide increases expression ISO RGD:1317596 6480464 Niclosamide results in increased expression of GABARAPL1 mRNA CTD PMID:36318118 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of GABARAPL1 mRNA CTD PMID:25729387 ozone multiple interactions ISO RGD:1317597 6480464 [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of GABARAPL1 mRNA CTD PMID:34911549 p-chloromercuribenzoic acid increases expression ISO RGD:1317596 6480464 p-Chloromercuribenzoic Acid results in increased expression of GABARAPL1 mRNA CTD PMID:26272509 paracetamol affects expression ISO RGD:1317597 6480464 Acetaminophen affects the expression of GABARAPL1 mRNA CTD PMID:17562736 paraquat increases expression ISO RGD:1317597 6480464 Paraquat results in increased expression of GABARAPL1 mRNA CTD PMID:12595580 parathion increases expression ISO RGD:1317597 6480464 Parathion results in increased expression of GABARAPL1 mRNA CTD PMID:34813904 perfluorooctane-1-sulfonic acid multiple interactions ISO RGD:1317597 6480464 [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of GABARAPL1 mRNA, [perfluorooctane sulfonic acid co-treated with Inulin] results in increased expression of GABARAPL1 mRNA CTD PMID:36331819 perfluorooctanoic acid increases expression ISO RGD:1317597 6480464 perfluorooctanoic acid results in increased expression of GABARAPL1 mRNA CTD PMID:26879310 phenethyl isothiocyanate increases expression ISO RGD:1317596 6480464 phenethyl isothiocyanate results in increased expression of GABARAPL1 mRNA CTD PMID:26678675 phenylmercury acetate increases expression ISO RGD:1317596 6480464 Phenylmercuric Acetate results in increased expression of GABARAPL1 mRNA CTD PMID:26272509 pirinixic acid decreases expression ISO RGD:1317597 6480464 pirinixic acid results in decreased expression of GABARAPL1 mRNA CTD PMID:18445702 pirinixic acid multiple interactions ISO RGD:1317596 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of GABARAPL1 mRNA CTD PMID:19710929 rotenone decreases expression ISO RGD:1317597 6480464 Rotenone results in decreased expression of GABARAPL1 mRNA CTD PMID:23186747 rotenone increases expression EXP 6480464 Rotenone results in increased expression of GABARAPL1 mRNA CTD PMID:28374803 silicon dioxide affects expression ISO RGD:1317596 6480464 Silicon Dioxide analog affects the expression of GABARAPL1 mRNA CTD PMID:25895662 silver atom increases expression ISO RGD:1317597 6480464 Silver results in increased expression of GABARAPL1 mRNA CTD PMID:27131904 silver(0) increases expression ISO RGD:1317597 6480464 Silver results in increased expression of GABARAPL1 mRNA CTD PMID:27131904 sirolimus multiple interactions ISO RGD:1317597 6480464 Sirolimus affects the localization of and results in increased lipidation of GABARAPL1 protein CTD PMID:15888080 sodium arsenite decreases expression ISO RGD:1317596 6480464 sodium arsenite results in decreased expression of GABARAPL1 mRNA CTD PMID:34032870 sulfadimethoxine decreases expression EXP 6480464 Sulfadimethoxine results in decreased expression of GABARAPL1 mRNA CTD PMID:30047161 sulforaphane increases expression ISO RGD:1317596 6480464 sulforaphane results in increased expression of GABARAPL1 mRNA CTD PMID:26833863 tetrachloromethane decreases expression ISO RGD:1317597 6480464 Carbon Tetrachloride results in decreased expression of GABARAPL1 mRNA CTD PMID:27339419 , PMID:31919559 theophylline multiple interactions ISO RGD:1317596 6480464 [Hydrogen Peroxide co-treated with Theophylline] results in increased expression of GABARAPL1 protein CTD PMID:18951874 titanium dioxide decreases expression ISO RGD:1317597 6480464 titanium dioxide results in decreased expression of GABARAPL1 mRNA CTD PMID:23557971 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in increased expression of GABARAPL1 mRNA CTD PMID:25729387 troglitazone decreases expression ISO RGD:1317597 6480464 troglitazone results in decreased expression of GABARAPL1 mRNA CTD PMID:28973697 troglitazone increases expression ISO RGD:1317596 6480464 troglitazone results in increased expression of GABARAPL1 mRNA CTD PMID:19140230 trovafloxacin increases expression ISO RGD:1317596 6480464 trovafloxacin results in increased expression of GABARAPL1 mRNA CTD PMID:33609687 trovafloxacin multiple interactions ISO RGD:1317596 6480464 [trovafloxacin co-treated with TNF protein] results in increased expression of GABARAPL1 mRNA CTD PMID:33609687 tunicamycin increases expression ISO RGD:1317596 6480464 Tunicamycin results in increased expression of GABARAPL1 mRNA CTD PMID:22378314 , PMID:33545341 urethane increases expression ISO RGD:1317596 6480464 Urethane results in increased expression of GABARAPL1 mRNA CTD PMID:28818685 valdecoxib increases expression EXP 6480464 valdecoxib results in increased expression of GABARAPL1 mRNA CTD PMID:24136188 valproic acid increases expression ISO RGD:1317596 6480464 Valproic Acid results in increased expression of GABARAPL1 mRNA CTD PMID:19101580 , PMID:29154799 valproic acid increases expression ISO RGD:1317597 6480464 Valproic Acid results in increased expression of GABARAPL1 mRNA CTD PMID:20546886 vinclozolin affects expression EXP 6480464 vinclozolin affects the expression of GABARAPL1 mRNA CTD PMID:19015723 zinc atom multiple interactions ISO RGD:1317596 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of GABARAPL1 mRNA CTD PMID:18593933 zinc(0) multiple interactions ISO RGD:1317596 6480464 [PCI 5002 co-treated with Zinc] results in increased expression of GABARAPL1 mRNA CTD PMID:18593933 zoledronic acid decreases expression ISO RGD:1317596 6480464 zoledronic acid results in decreased expression of GABARAPL1 mRNA CTD PMID:24714768 , PMID:25596134